ENT Specialty Healthcare Provider Renshu Medical Completes Tens of Millions RMB Series A Funding Led by Eight Roads and F-Prime Capital

VCBeat has learned that Renshu Medical announced on February 26 the completion of its tens-of-millions-of-yuan Series A financing round, led by SDAO Capital and F-Prime, with existing investor Huachuang Capital continuing to participate. Renshu Medical is a comprehensive outpatient and ambulatory surgery center specializing in ophthalmology, otolaryngology (ear, nose, and throat). Its first ambulatory surgery center opened in Hangzhou in July 2017. The new capital will be used to establish new medical facilities in the Yangtze River Delta region.

Thanks to advances in anesthesia and minimally invasive surgical techniques, as well as improvements in the quality and efficiency of healthcare services, ambulatory surgery has emerged and is now widely practiced across countries worldwide. In the United States, the volume of same-day, non-admission ambulatory surgeries has long far exceeded that of inpatient procedures, with otolaryngology–head and neck surgery accounting for 24% of all ambulatory surgeries. In China, ambulatory surgery is increasingly promoted by the government due to the advantages of its care model. In the Key Tasks for Deepening Healthcare Reform in 2017, the State Council called on localities to launch pilot programs for ambulatory surgery in tertiary hospitals. That same year, the Zhejiang Provincial Health and Family Planning Commission took the lead in issuing a recommended catalog comprising 158 ambulatory surgery diagnoses and procedures.

Otorhinolaryngology and ophthalmology diseases are diverse, have a high incidence rate, and significantly impact quality of life; surgery is the most common and effective treatment. However, public hospitals face long surgical waiting lists, with an average hospital stay of 5–7 days, creating an urgent market demand for high-quality private medical services.

Targeting this market, Renshu Medical has developed dozens of day-surgery protocols for common, frequently occurring, chronic, and complex ENT (ear, nose, and throat) conditions. By leveraging state-of-the-art medical equipment and personalized treatment plans, the company enables the vast majority of patients to complete surgery, observation, and recovery on the same day, adhering to the principles of safety, efficacy, and convenience. Furthermore, Renshu has introduced and implemented an internationally benchmarked healthcare system, led by domestic and foreign experts with deep specialization in ophthalmology and ENT care, aligning its practices with international clinical standards.

Ms. Xu Jinghuan, Founder and CEO of Renshu Medical, stated, “Day surgery has been developing since the 1980s. Today in Europe and the United States, 70% or even more of elective procedures in otolaryngology are performed as day surgeries. However, this proportion remains very low in China; in first-tier and near-first-tier cities such as Hangzhou, Shanghai, and Beijing, it is likely below 5%, indicating substantial market demand. Furthermore, ‘safety, efficiency, and compassion’ are the core principles upheld by Renshu Medical. While introducing international safety management standards and top-tier branded medical equipment, we also emphasize integrating high-quality local medical resources and technical support. Our medical team consists of expert attending physicians from renowned Grade A tertiary hospitals, enabling the international standard system to be adapted to local conditions and better implemented in China.”

“Renshu Medical’s efficient workflow—booking a specialist appointment in 1 minute, completing consultations and examinations within 1 hour, and achieving same-day surgery and discharge—has gained favor among individuals living at the fast pace of modern society, while significantly improving the utilization of high-quality medical resources.”

It is reported that Renshu Medical’s ambulatory surgery center in Hangzhou, having been open for just over a year, has attracted a large number of renowned physicians and patients with its specialized medical services. By the end of 2018, it had served nearly 10,000 patient visits. In addition to otorhinolaryngology (ENT), Renshu Medical has expanded its offerings to include a series of specialized clinics led by renowned experts, such as adolescent gynecology, orthopedics, and pediatric surgery.

In terms of service, to meet patients’ actual needs—particularly to reduce surgical risks in pediatric cases—we have innovatively introduced a service model that combines multiple surgical procedures under a single general anesthesia session through multidisciplinary collaboration, significantly enhancing patient experience. In 2018, after six months of rigorous professional evaluation, Renshu Medical became the first ambulatory surgery center in Zhejiang Province to receive the Ping An Wanjia Four-Star Certification. Moving forward, we will continue to dedicate ourselves to the ongoing improvement of standardized operational procedures and management systems for ambulatory surgery.

Ms. Lin Rui, Partner at STO Capital, stated, “Day surgery centers represent a new model in China. Renshu Medical has conducted pioneering exploration and practice in the field of day surgeries for ophthalmology, otolaryngology, and related specialties. By steadily advancing and striving for excellence in procedural development, establishment of clinical standard pathways, and refined operational management, the company has consistently upheld medical quality, safety, and efficacy as its highest principles. This approach has effectively met the needs of a broad patient base and created substantial social value. We are honored to collaborate with Mr. Xu and the Renshu team, supporting Renshu Medical in sustaining high-quality business expansion from a strong foundation. Furthermore, we will leverage STO Capital’s localized professional resources and global healthcare network to facilitate Renshu Medical’s development.”

Renshu Medical is a specialized ENT healthcare brand that has introduced the high-end medical systems of Europe and America, with a large number of top-tier renowned physicians joining its team. In addition to providing high-quality diagnostic and treatment services, it is committed to delivering premium and attentive specialized medical care experiences through solutions such as minimally invasive day-surgery centers aligned with global standards, internet technology, wearable medical devices, and personalized chronic disease rehabilitation therapies.

Fidelity Growth Partners is a global venture capital firm dedicated to supporting ambitious entrepreneurs. With over 20 years of venture capital experience in China, it has invested in more than 85 companies across sectors including healthcare, enterprise IT, fintech, and consumer industries. As the proprietary investment arm of Fidelity International, Fidelity Growth Partners is committed to backing bold and impactful enterprises. Over the past decade, Fidelity Growth Partners and its affiliated funds have invested nearly $6 billion globally in growth-stage companies. In China’s healthcare sector, Fidelity Growth Partners boasts over two decades of investment expertise, focusing on early-stage healthcare investments and building a strategic layout across the entire industry chain. To date, its total cumulative investment in China’s healthcare sector exceeds $650 million.

F-Prime Capital is a global venture capital firm focused on the life sciences, healthcare, and technology sectors. Since 1969, F-Prime has worked closely with entrepreneurs and academics to deliver innovative solutions to some of the most significant challenges in healthcare and technology worldwide.